Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
250.00    0.00 (0.00%)
Bid:
245.00
Ask:
255.00
Spread: 10.00 (4.082%)
Market Cap: £227.11m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Board Changes

12 May 2021 09:00

RNS Number : 2860Y
Concurrent Technologies PLC
12 May 2021
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain

 

12 May 2021

 

Concurrent Technologies Plc

 

Board Changes

 

Concurrent Technologies Plc (AIM: CNC), a world leading specialist in the design and manufacture of high-performance embedded computer boards for critical applications, is pleased to announce the appointment of Dr Miles Adcock as Chief Executive Officer and as an executive director of the Company with effect from 21 June 2021.

 

The Company also announces today that Jane Annear, Managing Director, has given notice of her retirement after 36 years of outstanding service to the Company. Jane will work to support Miles in her remaining time with the Company in order to ensure an orderly transition and will continue as an executive director of the Company during that time.

 

Dr Miles Adcock is currently President of Space Imaging at Teledyne Technologies Inc. Prior to joining Teledyne, Miles held senior roles at QinetiQ Group plc including as Managing Director of its Cyber, Information & Training business unit and as Group Engineering Director. He has previously worked at BAE Systems and GEC Marconi. A Chartered Engineer and a Chartered Physicist, he received his PhD in Adaptive Optics from Imperial College, London.

 

Mark Cubitt, Non-executive Chairman of Concurrent Technologies, commented:

 

"We are delighted to welcome Miles as Chief Executive Officer of Concurrent Technologies. His experience in growing international based technology companies will help drive forward the Company to take the next steps in our development as a leading player in the high performance embedded market. It is also important we recognise today the significant role Jane has played in the growth of the Company, which she has served since she joined as our second employee on incorporation in 1985."

 

Dr Miles Adcock commented:

 

"I am very pleased to take up this role. Concurrent Technologies is a fantastic organisation. We have great people and technological capabilities and a competitive customer offering. I look forward to leading Concurrent Technologies in its next phase of growth and creating value for all our stakeholders."

 

Jane Annear, Managing Director, commented:

 "It has been a privilege to lead the team at Concurrent Technologies for the last 2 years and I would like to thank all of our employees for their commitment and support during that time. I am pleased to welcome Miles to the role of Chief Executive Officer in a new and exciting era for the Company."

 

 

 

 

Enquiries:

 

Concurrent Technologies PlcJane Annear, Managing Director

 

+44 (0)1206 752626

Newgate (Financial PR)Bob Huxford

Isabelle Smurfit

 

+44 (0)20 7653 9848+44 (0)20 3757 3411

Cenkos Securities Plc (NOMAD)Neil McDonald

Peter Lynch

+44 (0)131 220 9771

+44 (0)131 220 9772

 

The following information regarding the appointment of Dr Miles Adcock (aged 48) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

Full Name:

Miles John Adcock

 

Current Directorship / Partnerships:

South East LEP Limited

Teledyne e2v Ltd

Teledyne UK Limited

 

Previous Directorship / Partnerships:

BJ Trustee Limited

Bolden James Limited

Cuesim Limited

Gyldan 11 Limited

Leading Technology Limited

Qinetiq Special Project Inc.

 

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

 

Note to Editors:

 

About Concurrent Technologies Plc

 

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high performance, long life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest 9th generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom® processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

 

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

 

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAKSFFFLFEFA
Date   Source Headline
29th Oct 20099:07 amRNSProduct Launch
26th Oct 200911:21 amRNSHolding(s) in Company
22nd Oct 20092:48 pmRNSHolding(s) in Company
15th Oct 20097:00 amRNSProduct Launch
28th Sep 20093:39 pmRNSHolding(s) in Company
28th Sep 20091:14 pmRNSHolding(s) in Company
3rd Sep 20097:00 amRNSHalf Yearly Report
2nd Sep 20097:00 amRNSProduct Launch
1st Sep 200912:02 pmRNSTotal Voting Rights
28th Aug 20092:39 pmRNSHolding(s) in Company
28th Aug 20092:38 pmPRNNotice of Results
19th Aug 20098:48 amPRNProduct Launch
23rd Jul 20099:59 amPRNProduct Launch
1st Jul 20092:44 pmRNSTreasury Shares
30th Jun 20095:04 pmRNSTotal Voting Rights
30th Jun 20093:15 pmRNSDirector/PDMR Shareholding
22nd Jun 20093:27 pmRNSTransaction in Own Shares
4th Jun 20094:11 pmRNSHolding(s) in Company
2nd Jun 20093:06 pmRNSHolding(s) in Company
20th May 20094:35 pmRNSDistribution of Annual Report & Accounts
20th May 20093:09 pmRNSHolding(s) in Company (Replacement)
20th May 20092:44 pmRNSHolding(s) in Company
18th May 20094:10 pmRNSHolding(s) in Company
5th May 20094:11 pmRNSHolding(s) in Company
27th Apr 20097:00 amPRNFinal Results
20th Apr 20092:13 pmRNSNotice of Results
16th Apr 20094:57 pmRNSHolding(s) in Company
2nd Apr 20097:00 amPRNProduct Launch
9th Mar 20092:32 pmRNSTotal Voting Rights
4th Feb 20097:00 amRNSTransaction in Own Shares
6th Jan 200912:12 pmPRNTrading Statement
5th Dec 20084:02 pmPRNProduct Launch
4th Dec 20084:00 pmPRNDirector/PDMR Shareholding
28th Nov 200810:51 amRNSTotal Voting Rights
21st Nov 20088:00 amRNSTransaction in Own Shares
10th Nov 200810:26 amPRNProduct Launch
7th Nov 20082:46 pmRNSTransaction in Own Shares
4th Nov 20088:00 amRNSTransaction in Own Shares
31st Oct 200812:05 pmRNSTotal Voting Rights
24th Oct 20087:00 amRNSTreasury Shares
22nd Oct 20087:00 amRNSTreasury Shares
21st Oct 20083:14 pmRNSDirector/PDMR Shareholding
21st Oct 200812:27 pmRNSDirector/PDMR Shareholding
17th Oct 20081:43 pmRNSTreasury Shares
10th Oct 20081:16 pmRNSTransaction in Own Shares
2nd Oct 20083:50 pmPRNDistribution of Half-yearly Report
30th Sep 20083:58 pmRNSTotal Voting Rights
26th Sep 20084:06 pmPRNProduct Launch
4th Sep 20087:00 amPRNHalf-yearly Report
1st Sep 20084:17 pmPRNNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.